Adversity is less terrifying than hope: Companhia Brasileira De Distribuicao (CBD)

Companhia Brasileira De Distribuicao (NYSE: CBD) stock fell -0.88% on Tuesday to $3.36 against a previous-day closing price of $3.39. With 0.97 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.32 million shares. During the session, the Department Stores company that operates in wider Consumer Cyclical sector, reached to the highest price of $3.4500 whereas the lowest price it dropped to was $3.3150. The 52-week range on CBD shows that it touched its highest point at $4.43 and its lowest point at $2.54 during that stretch. It currently has a 1-year price target of $2.80. With its current market cap of 917.75 million, CBD has annualized dividend of $0.07 while the current yield stands at 2.11%. Beta for the stock currently stands at 1.26.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CBD was down-trending over the past week, with a drop of -0.59%, but this was up by 3.38% over a month. Three-month performance surged to 1.51% while six-month performance rose 1.51%. The stock lost -20.19% in the past year, while it has gained 8.39% so far this year. A look at the trailing 12-month EPS for CBD yields -0.77 with Next year EPS estimates of -0.47. For the next quarter, that number is 0.01. This implies an EPS growth rate of -112.70% for this year and -571.40% for next year.

Float and Shares Shorts:

At present, 269.98 million CBD shares are outstanding with a float of 158.93 million shares on hand for trading. On Apr 27, 2023, short shares totaled 2.23 million, which was 0.83% higher than short shares on Mar 30, 2023. In addition to Mr. Marcelo Ribeiro Pimentel as the firm’s CEO & Director, Mr. Guillaume Marie Didier Gras serves as its CFO, Investors Relations Director & Member of Exec. Board.

Institutional Ownership:

Through their ownership of 4.53% of CBD’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.94% of CBD, in contrast to 1.12% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CBD with 0.43% of the stake, SPX Gestão de Recursos Ltda. holds 1,153,228 shares worth 1,153,228. A second-largest stockholder of CBD, UBS Switzerland AG, holds 1,045,100 shares, controlling over 0.39% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in CBD, holding 830,388 shares or 0.31% stake. With a 0.18% stake in CBD, the Vanguard Total International Stoc is the largest stakeholder. A total of 476,044 shares are owned by the mutual fund manager. The Avantis Emerging Markets Equity E, which owns about 0.16% of CBD stock, is the second-largest Mutual Fund holder. It holds 424,197 shares valued at 1.29 million. SPDR Portfolio Emerging Markets E holds 0.14% of the stake in CBD, owning 365,692 shares worth 1.11 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, CBD reported revenue of $10.12B and operating income of $279.00M. The EBITDA in the recently reported quarter was $692.00M and diluted EPS was -$0.64.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CBD since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CBD analysts setting a high price target of $5.98 and a low target of $2.77, the average target price over the next 12 months is $4.01. Based on these targets, CBD could surge 77.98% to reach the target high and fall by -17.56% to reach the target low. Reaching the average price target will result in a growth of 19.35% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Leave a Comment

Your email address will not be published. Required fields are marked *